HEALTH ALERT! If you have any of the following, please call our office before coming in for your appointment: Fever AND cough; Fever OR cough and recent travel (domestic or international to any destination); Recent international travel to areas impacted by the Coronavirus (2019-nCoV) within the last 14 days; OR close contact with someone who has traveled outside the US or been exposed to the Coronavirus. Read more
Available Trials
Breast
-
USOR 20258: PH2 GDC-9545 ER+/HER2- MBC
A Phase II, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Compared with Physician's Choice of Endocrine Monotherapy in Patients With Previously Treated Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (WO42312)
Available at Arlington Heights, Niles
-
USOR 19054: STAR Ph3 Tuca/Placebo + T-DM1 HER2+
A Randomized, Double-Blind, Phase 3 Study of Tucatinib or Placebo in Combination with Ado-Trastuzumab Emtansine (T-DM1) for Subjects with Unresectable, Locally-Advanced, or Metastatic HER2+ Breast Cancer. (HER2CLIMB-02)(SGNTUC-016)
Available at Arlington Heights, Niles
Cholangiocarcinoma
-
USOR 18264 STAR Infigratinib vs Gem/Cis Cholangio
A Phase 3, Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations. The PROOF Trial (QBGJ398-301)
Available at Arlington Heights, Niles
Colorectal
-
USOR 19245: Ph3 Fruq + Placebo CC (FRESCO-2)
NOW OPEN: A Global, Multicenter, Randomized, Placebo-Controlled Phase 3 Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care to Placebo Plus Best Supportive Care in Patients with Refractory Metastatic Colorectal Cancer (2019-013-GLOB1)
Available at Arlington Heights
-
USOR 20235: PH3 Trila FOLFOXIRI Beva CC
NOW OPEN PRESERVE 1: A Phase 3 Randomized, Double-Blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (G1T28-207)
Available at Arlington Heights, Niles
-
USOR 20157: Plasma Test ColoRec Cancer
PREEMPT CRC: PREvention Employing a Multiomics Plasma-based Test for ColoRectal Cancer (FRNM-004)
Available at Arlington Heights
-
USOR 18261: Ph3b Nivo + lpi MSI-H, mCRC
A Phase 3b Randomized Clinical Trial of Nivolumab Alone, or in Combination with Ipilimumab, or an Investigator's Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer. (CA2098HW)
Available at Arlington Heights, Niles
Endometrial
-
USOR 19221: PH3 Plac Carbo Pacil Dura +/- Olap DUO -E
A Randomized, Multicentre, Double-Blind, Placebo-Controlled, Phase III Study of First-Line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer. (DUO-E) (D9311C00001)(GOG-3041)(ENGOT-EN10)
Available at Arlington Heights, Niles
Gynecological/Ovarian
-
USOR 20225 STAR Ph2 Ak104 Cervical Cancer
A Phase 2, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of AK104 in Subjects with Recurrent or Metastatic Cervical Cancer (AK104-201-AU) (Akesobio Australia)
Available at Arlington Heights
-
USOR 19200: PH3 Mirve Sora Fallopian
MIRASOL: A Randomized, Open-Label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression. (IMGN853-0416)
Available at Arlington Heights, Niles
Hematology
-
USOR 18130: Ph3 Itacitinib GVHD (GRAVITAS309)
INCB 39110-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)
Available at Niles
-
USOR 08160: PNH Registry
PNH Registry: Primary Objective of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry will Collect Data to Evaluate Safety Data Specific to the Use of Solaris and to Characterize the Progression of PNH as well as Clinical Outcomes, Mortality and Morbidity in Solaris and Non-Solaris Treated Patients. Secondary Objective is Raising PNH Awareness in the Medical Community and Patient/Potential Patient Population. (M07-001)
Available at Niles, Arlington Heights
Leukemia
-
USOR 19205: Ph2 Ublitux + Umbralisib+ Venetoclax CLL
ULTRA-V: A Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)
Available at Arlington Heights, Niles
Lung - Non-Small Cell Lung
-
USOR 20331 STAR Ph2 VS-6766 FAK inhib KRAS-MT NSCLC
NOW OPEN: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (VS-6766-202) (Verastem)
Available at Niles
-
USOR 20269 STAR PH3 MRTX849 Doce NSCLC
New: A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-012) (Mirati Therapeutics)
Available at Arlington Heights, Niles
-
USOR 20270 Ph2 MRTX849 Pembro NSCLC KRAS
NEW: A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation. (849-007) (Mirati Therapeutics)
Available at Arlington Heights, Niles
-
USOR 20381: MYLUNG Study Part 2
NEW Observational Research Trial to Improve Testing and Treatment Protocols for NSCLC: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium)
Available at Arlington Heights, Niles
-
USOR 20137: PH3 Atez Tira Dura Sg 3 NSCLC
A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients with Locally Advanced, Unresectable, Stage III, Non-Small Cell Lung Cancer, Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation (SKYSCRAPER-03) (GO41854)
Available at Arlington Heights, Niles
-
USOR 19018: Ph 3 Sit + Nivo vs. Docetaxel NSCLC
516-005: A Randomized, Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)
Available at Arlington Heights, Niles
-
USOR 19192: Ph3 Tira atezo NSCLC
A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, An Anti-Tigit Antibody, In Combination with Atezolizumab, Compared with Placebo In Combination With Atezolizumab, In Patients With Previously Untreated, Locally Advanced, Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer. (GO41717)
Available at Arlington Heights, Niles
-
USOR 19044: Ph 3 Durv vs. plbo SBRT NSCLC (PAC 4)
D9103C00001: A Phase III, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Unresected Stage I/II, Lymph-Node Negative, Non-Small Cell Lung Cancer. (PACIFIC-4/RTOG-3515)
Available at Niles
Lymphoma
-
USOR 20343 Ph3 LOXO-305 vs Inv Choice IdeIR or BR
Now Open: A Phase 3, Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)
Available at Arlington Heights, Niles
-
USOR 19062: Ph 1b/3 Taze w/ R2 R/R Fol Lymph
A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma (EZH-302)
Available at Arlington Heights, Niles
-
USOR 20219: PH2 Brentux + CHP in Tx Naive PTCL
A Dual-Cohort, Open-Label, Phase 2, Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects with Peripheral T-Cell Lymphoma (PTCL) with Less Than 10% CD30 Expression. (SGN35-032)
Available at Niles
-
USOR 20144: PH3 Bren Vedo Lena Ritux r/r BC Lymph
A Randomized, Double-Blind, Placebo-Controlled, Active-Comparator, Multi-Center, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.(SGN35-031)
Available at Arlington Heights, Niles
-
USOR 16065: TGR-1202 +/- Ublituximab in NHL
A Phase 2b, Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma. (UTX-TGR-205)
Available at Niles, Arlington Heights
-
USOR 11282: STAR BV in pts w/1L cHL or PTCL
A Phase 2, Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients with Significant Comorbidities Ineligible for Standard Chemotherapy.(SGN35-015)
Available at Niles
Multiple Myeloma
-
USOR 19247: PH3 Dara/Len vs Len NDMM
A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)
Available at Arlington Heights, Niles
Myelomas
-
USOR 18230: Ph3 R/R MM (DREAMM 7)
DREAMM 7: A Multicenter, Open- Label, Randomized, Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma (207503.)
Available at Arlington Heights, Niles
Pancreas
-
USOR 17160: PANOVA-3 1L Gemcit + nab-pac pancreatic
PANOVA-3: Pivotal, Randomized, Open-Label Study of Tumor Testing Fields (TTFields, 150kHz) concomitant with Gemcitabine and Nab-Paclitaxel for Front-Line Treatment of Locally-Advanced Pancreatic Adenocarcinoma (EF-27)
Available at Niles, Arlington Heights
PNH
-
USOR 08160: PNH Registry
PNH Registry: Primary Objective of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry will Collect Data to Evaluate Safety Data Specific to the Use of Solaris and to Characterize the Progression of PNH as well as Clinical Outcomes, Mortality and Morbidity in Solaris and Non-Solaris Treated Patients. Secondary Objective is Raising PNH Awareness in the Medical Community and Patient/Potential Patient Population. (M07-001)
Available at Niles, Arlington Heights
Prostate
-
USOR 19191: Ph3 Docetaxel +/- Nivo mCRPC
A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo, In Combination With Docetaxel, in Men with Metastatic, Castration-Resistant, Prostate Cancer. (CA209-7DX)
Available at Arlington Heights, Niles
Solid Tumor
-
USOR 19151: STAR Ph1/2 MRTX849 Solids KRAS G12C
A Phase 1/2, Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Sold Tumors with KRAS G12C Mutation (849-001)
Available at Niles
-
USOR 19079: STAR Ph2 Pemigatinib Solids FGFR
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)(INCB54828-207)
Available at Arlington Heights
STAR: Selected Trials Available for Accelerated Four Week Rollout
-
USOR 17144 STAR Ph 1b/2 Cavrotolimod + Pembro Cemip ST
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors: A Phase 1b/2 Study of Cavrotolimod Combined with Pembrolizumab or Cemiplimab (AST-008-102)
Available at Arlington Heights, Niles
-
SOLID TUMORS: USOR 20344 STAR Ph2 Basket Tucat+Tras ST HER2 Alt
A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advance Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019) (Seattle Genetics)
Available at Arlington Heights, Niles
-
UROTHELIAL CANCER: USOR 18033 STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro
A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients with Advanced or Metastatic Urothelial Carcinoma (516-003) (Mirati Therapeutics)
Available at Arlington Heights, Niles
-
UROTHELIAL CANCER: USOR 17133 STAR Ph3 FGFR erdafitinib urothelial
A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR) (42756493BLC3001) (Janssen)
Available at Arlington Heights, Niles
-
UROTHELIAL CANCER: USOR 20172 STAR PH 2 Enfortumab in Urothelial Pts
A Study of Enfortumab Vedotin (ASG-22CE) as Monotherapy or in Combination with Other Anticancer Therapies for the Treatment of Urothelial Cancer (SGN22E-002) (Seattle Genetics)
Available at Arlington Heights, Niles
-
SOLID TUMORS: USOR 18164 STAR Ph1/2 BLU667 thy, NSCLC, Sol tum
A Phase 1/2 Study of the Highly-Selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumors (BLU-667-1101) (Blueprint Medicines)
Available at Arlington Heights, Niles
-
SOLID TUMORS: USOR 19092 STAR Ph2 Erdafitinib FGFR Solid Tumors
A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002) (Janssen)
Available at Arlington Heights, Niles
-
SOLID TUMORS: USOR 20245 STAR Ph2 Seribantumab NRG1 Fusion+ ST
A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01) (Elevation Oncology)
Available at Arlington Heights, Niles
-
SKIN CANCER: USOR 18014 STAR Ph1 CX-4945 Basal Cell Carcinoma
A Phase I, Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and Pharmacodynamic Study of CX-4945 Administered Orally, Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07) (Senhwa Biosciences)
Available at Arlington Heights, Niles
-
PROSTATE CANCER: USOR 16238 STAR Rucaparib v PhysC mCRPC (TRITON3)
A Multicenter, Randomized, Open-Label, Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer Associated with Homologous Recombination Deficiency (CO-338-063) (Clovis Oncology)
Available at Arlington Heights, Niles
-
PROSTATE CANCER: USOR 18103 STAR Ph3 Nirap+Abirat+Pred mCRPC
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer (64091742PCR3001) (Janssen)
Available at Arlington Heights, Niles
-
PROSTATE CANCER: USOR 20248 STAR PH3 Nirap Abira HRR mCSPC
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (67652000PCR3002) (Janssen)
Available at Arlington Heights, Niles
-
MYELOFIBROSIS: USOR 19171 STAR PH3 Pacritinib vs MD Choice in MF
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/uL) (PAC203) (CTI BioPharma)
Available at Arlington Heights, Niles
-
MYELOFIBROSIS: USOR 20177 STAR Ph3 Navi Ruxo
A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (M16-191) (TRANSFORM-1) (AbbVie)
Available at Arlington Heights, Niles
-
LYMPHOMA: USOR 18013 STAR Ph2 A+AVD +G-CSF or AOAD in CHL
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects (SGN35-027) (Seattle Genetics)
Available at Arlington Heights, Niles
-
LUNG CANCER: USOR 18129 STAR Ph3 ALK+ mNSCLC (Brigatinib-3001)
A Phase 3, Randomized, Open-Label, Study of Brigatinib (ALUNBRIG) Versus Alectinib (ALECENSA) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI) (Takeda)
Available at Arlington Heights, Niles
-
LUNG CANCER: USOR 19208 STAR-PH3 pral (Blu-667) RET-fusion mNSCLC
A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303) ( Blueprint Medicines)
Available at Arlington Heights, Niles
-
LUNG CANCER: USOR 19239 STAR KEAP1/NRF2 NSCLC
"KEAPSAKE" A Phase 2, Randomized, Multicenter, Double-Blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-Line Metastatic KEAP1/NRF2-Mutated Nonsquamous, Non-Small Cell Lung Cancer (CX-839-014) (Calithera Biosciences)
Available at Arlington Heights, Niles
-
LUNG CANCER: USOR 20249 STAR PH3 JNJ-61186372 Peme EGFR NSCLC
A Randomized, Open-Label, Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001) (Janssen)
Available at Arlington Heights, Niles
-
LUNG CANCER: USOR 20250 STAR Ph3 61186372 Osim Lazert EGFR NSCLC
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (73841937NSC3003) (MARIPOSA) (Janssen)
Available at Arlington Heights, Niles
-
OVARIAN CANCER: USOR 20298 STAR Ph2 VS-6766 Fak-Inhib LGSOC
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-201) (GOG 3052) (Verastem)
Available at Arlington Heights, Niles
-
ESOPHAGEAL CANCER: USOR 20171 STAR Ph3 Sinti vs Placebo ESCC
A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, For First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15) (CIBI308A301) (Innovent Biologics)
Available at Arlington Heights, Niles
-
COLORECTAL CANCER: USOR 20216 STAR PH2 Tuca+ Tras HER2+ CC
A Phase 2, Open-Label Study of Tucatinib, Combined with Trastuzumab, in Patients With HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617, SGNTUC-017) (Seattle Genetics)
Available at Arlington Heights, Niles
-
BREAST CANCER: USOR 14059 STAR Ph1/2 Ibrutinib+Tras HER2 amp/MBC
A Phase I/II Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer (14059) (Pharmacyclics)
Available at Arlington Heights, Niles
-
ANAL CANCER: USOR 20189 STAR Ph3 Carbo/Pac NCMGA00012 MSCC
A Phase 3 Global, Multicenter, Double-Blind, Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable, Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal, Not Previously Treated with Systemic Chemotherapy (INCMGA 0012-303) (Incyte)
Available at Arlington Heights, Niles
-
UROTHELIAL CANCER: USOR 19094 STAR Ph3 Infigratinib UC w/FGFR3 Alt
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations. (PROOF302) (QBGJ398-302) (QED Therapeutics)
Available at Arlington Heights, Niles